Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Shannon R. Morris"'
Autor:
Renata Ferrarotto, Ian Anderson, Balazs Medgyasszay, Maria Rosario García‐Campelo, William Edenfield, Trevor M. Feinstein, Jennifer M. Johnson, Sujith Kalmadi, Philip E. Lammers, Alfredo Sanchez‐Hernandez, Yili Pritchett, Shannon R. Morris, Rajesh K. Malik, Tibor Csőszi
Publikováno v:
Cancer Medicine, Vol 10, Iss 17, Pp 5748-5756 (2021)
Abstract Background Supportive care interventions used to manage chemotherapy‐induced myelosuppression (CIM), including granulocyte colony‐stimulating factors (G‐CSFs), erythropoiesis‐stimulating agents (ESAs), and red blood cell (RBC) transf
Externí odkaz:
https://doaj.org/article/67201ebc01a245ac809c92ab296cf9ee
Autor:
Razelle Kurzrock, Shannon R. Morris, Thomas A. Lampkin, Deborah A. Smith, Laurel Adams, Michael Durante, Joseph F. Kleha, Neeraj Agarwal, Emily Bergsland, E. Claire Dees, Theresa L. Werner, Petronella O. Witteveen, Jennifer Specht, Ruud van der Noll, Jan H.M. Schellens, David Hong, Rahul Aggarwal, Pamela Munster
Purpose: GSK2126458 (GSK458) is a potent inhibitor of PI3K (α, β, γ, and δ), with preclinical studies demonstrating broad antitumor activity. We performed a first-in-human phase I study in patients with advanced solid tumors.Materials and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b58210558b93cf8d4ce8c9aff837b458
https://doi.org/10.1158/1078-0432.c.6524799
https://doi.org/10.1158/1078-0432.c.6524799
Autor:
Razelle Kurzrock, Shannon R. Morris, Thomas A. Lampkin, Deborah A. Smith, Laurel Adams, Michael Durante, Joseph F. Kleha, Neeraj Agarwal, Emily Bergsland, E. Claire Dees, Theresa L. Werner, Petronella O. Witteveen, Jennifer Specht, Ruud van der Noll, Jan H.M. Schellens, David Hong, Rahul Aggarwal, Pamela Munster
Supplementary Table 1. Pharmacokinetic Parameters on Day 1 Following Once daily and Twice Daily Administration of GSK458 Supplementary Table 2. Best Objective Tumor Response by Dose Level (supplementary)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31cc3113a08b14c37c80c2acf0e81ea6
https://doi.org/10.1158/1078-0432.22461510
https://doi.org/10.1158/1078-0432.22461510
Autor:
Razelle Kurzrock, Shannon R. Morris, Thomas A. Lampkin, Deborah A. Smith, Laurel Adams, Michael Durante, Joseph F. Kleha, Neeraj Agarwal, Emily Bergsland, E. Claire Dees, Theresa L. Werner, Petronella O. Witteveen, Jennifer Specht, Ruud van der Noll, Jan H.M. Schellens, David Hong, Rahul Aggarwal, Pamela Munster
Duration of therapy and best objective response in the expansion cohorts (Breast, Bladder, Renal, and Endometrial Cancer)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87933980369fc59056a7f72a63d87c73
https://doi.org/10.1158/1078-0432.22461513
https://doi.org/10.1158/1078-0432.22461513
Autor:
Rajesh K. Malik, Yili Pritchett, Jennifer Johnson, Balazs Medgyasszay, Shannon R. Morris, Renata Ferrarotto, Trevor M. Feinstein, William Jeffery Edenfield, Maria Rosario García-Campelo, Ian Anderson, Tibor Csőszi, Alfredo Sanchez-Hernandez, Sujith Kalmadi, Philip E. Lammers
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 17, Pp 5748-5756 (2021)
Cancer Medicine, Vol 10, Iss 17, Pp 5748-5756 (2021)
Background Supportive care interventions used to manage chemotherapy‐induced myelosuppression (CIM), including granulocyte colony‐stimulating factors (G‐CSFs), erythropoiesis‐stimulating agents (ESAs), and red blood cell (RBC) transfusions, a
Autor:
Maen A. Hussein, Raid Aljumaily, Shannon R. Morris, Bojan Zaric, Wahid Hanna, Didier Verhoeven, Z. Andric, Jie Xiao, J. Thaddeus Beck, Janakiraman Subramanian, Renata Ferrarotto, Joyce M Antal, Davorin Radosavljevic, Lowell L. Hart, Taofeek K. Owonikoko
Publikováno v:
Advances in therapy
Advances in Therapy
Advances in Therapy
Introduction Multilineage myelosuppression is an acute toxicity of cytotoxic chemotherapy, resulting in serious complications and dose modifications. Current therapies are lineage specific and administered after chemotherapy damage has occurred. Tril
Autor:
Yili Pritchett, Jana Jaal, Davey B. Daniel, Iveta Kudaba, Vladimer Kuchava, Joyce M Antal, Oleksandr Ivashchuk, Lowell L. Hart, Jessica A. Sorrentino, Igor Bondarenko, Jerome H. Goldschmidt, Amiran Matitashvili, Sreekanth Reddy, Shannon R. Morris
Publikováno v:
International Journal of Cancer
Trilaciclib is an intravenous CDK4/6 inhibitor administered prior to chemotherapy to preserve haematopoietic stem and progenitor cells and immune system function from chemotherapy‐induced damage (myelopreservation). The effects of administering tri
Autor:
Brant A. Inman, Matthew I. Milowsky, Raj S. Pruthi, Marshall Posner, Melissa J. Polasek, Shannon R. Morris, Lori Mixson, Kristin Orr, Elizabeth M. H. Woodson, Andrea T. Kelly, W. Garrett Nichols, Arjun V. Balar
Publikováno v:
Molecular Cancer Therapeutics. 20:P045-P045
Background: PVSRIPO, a novel intratumoral viral immunotherapy, infects cells via CD155, which is widely expressed on solid tumors and antigen-presenting cells (APC). Infection is lethal in malignant cells, but a unique, activating, nonlethal infectio
Autor:
Brant A. Inman, Raj S. Pruthi, Andrea Kelly, Kristin Orr, Lori Mixson, Elizabeth M. H. Woodson, Matthew I. Milowsky, Shannon R. Morris, Arjun Vasant Balar, Melissa J. Polasek, Marshall R. Posner, Garrett Nichols
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPVSRIPO, a novel intratumoral viral immunotherapy, infects cells via CD155, which is widely expressed on solid tumors and antigen-presenting cells (APC). Infection is lethal in malignant cells, but a unique, activating, nonlethal infection
Autor:
Rajesh K. Malik, Petros Nikolinakos, Ralph V. Boccia, Konstantin H. Dragnev, Shannon R. Morris, Robert Hoyer, Donald A. Richards, Taofeek K. Owonikoko, A. Lowczak, Patrick J. Roberts, Vi Kien Chiu, J.T. Beck, Tibor Csoszi, Raid Aljumaily, Lowell L. Hart, I. Bulat, Maen A. Hussein, P. Sawrycki, Jessica A. Sorrentino, M. Maglakelidze, C.M. Rocha Lima, S. Adler, Jared Weiss, Zhao Yang, Joyce M Antal, S.R. Schuster, Wahid Hanna, M. Domine Gomez, Anne Y. Lai, John T. Hamm
Publikováno v:
Annals of Oncology
Background Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intravenous CDK4/6 inhibitor in development to proactively preserve HSPC and immune system function duri